High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy
(2012) In European Journal of Haematology 89(5). p.395-402- Abstract
- Objectives To determine whether serum vascular endothelial growth factor (s-VEGF) levels and VEGF gene expression in tumor tissue predict survival of diffuse large B-cell lymphoma (DLBCL) patients treated with chemoimmunotherapy. Methods VEGF levels were measured in serum samples from 102 patients <65yrs with high-risk DLBCL using a quantitative sandwich enzyme immunoassay technique. Exon array data set of tumor tissues from 32 patients was concurrently used to determine VEGF-A exon and gene expression. All patients were treated in a Nordic phase II study with six dose-dense chemoimmunotherapy courses followed by systemic central nervous system prophylaxis. Results After a median follow-up time of 40months, 3-yr progression-free... (More)
- Objectives To determine whether serum vascular endothelial growth factor (s-VEGF) levels and VEGF gene expression in tumor tissue predict survival of diffuse large B-cell lymphoma (DLBCL) patients treated with chemoimmunotherapy. Methods VEGF levels were measured in serum samples from 102 patients <65yrs with high-risk DLBCL using a quantitative sandwich enzyme immunoassay technique. Exon array data set of tumor tissues from 32 patients was concurrently used to determine VEGF-A exon and gene expression. All patients were treated in a Nordic phase II study with six dose-dense chemoimmunotherapy courses followed by systemic central nervous system prophylaxis. Results After a median follow-up time of 40months, 3-yr progression-free survival (PFS) was inferior in patients with high s-VEGF levels compared to those with low levels (59% vs. 83%, P=0.005). The relative risk of progression or relapse was 3.1-fold (95% confidence interval 1.346.91, P=0.008). The predictive capacity of s-VEGF levels on PFS was most pronounced in the DLBCLs of non-germinal center subtype. In contrast to serum data, VEGF mRNA expression in the lymphoma tissue did not predict outcome, and no correlation was found between s-VEGF levels and lymphoma VEGF expression. Conclusion Pretreatment s-VEGF level is a predictor of PFS after chemoimmunotherapy and may help to further stratify high-risk DLBCL patients into low- and high-risk groups. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3284153
- author
- Riihijarvi, Sari ; Nurmi, Heidi ; Holte, Harald ; Bjorkholm, Magnus ; Fluge, Oystein ; Pedersen, Lars Moller ; Fjordén, Karin LU ; Jerkeman, Mats LU ; Eriksson, Mikael LU and Leppa, Sirpa
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- diffuse large B-cell lymphoma, prognostic factors, vascular endothelial, growth factor, serum, ELISA, gene expression, exon array
- in
- European Journal of Haematology
- volume
- 89
- issue
- 5
- pages
- 395 - 402
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000309917500003
- scopus:84867467631
- pmid:22882209
- ISSN
- 1600-0609
- DOI
- 10.1111/ejh.12005
- language
- English
- LU publication?
- yes
- id
- 44789e23-0e3d-48e4-ad90-2b626db910fc (old id 3284153)
- date added to LUP
- 2016-04-01 10:27:55
- date last changed
- 2022-04-27 22:25:12
@article{44789e23-0e3d-48e4-ad90-2b626db910fc, abstract = {{Objectives To determine whether serum vascular endothelial growth factor (s-VEGF) levels and VEGF gene expression in tumor tissue predict survival of diffuse large B-cell lymphoma (DLBCL) patients treated with chemoimmunotherapy. Methods VEGF levels were measured in serum samples from 102 patients <65yrs with high-risk DLBCL using a quantitative sandwich enzyme immunoassay technique. Exon array data set of tumor tissues from 32 patients was concurrently used to determine VEGF-A exon and gene expression. All patients were treated in a Nordic phase II study with six dose-dense chemoimmunotherapy courses followed by systemic central nervous system prophylaxis. Results After a median follow-up time of 40months, 3-yr progression-free survival (PFS) was inferior in patients with high s-VEGF levels compared to those with low levels (59% vs. 83%, P=0.005). The relative risk of progression or relapse was 3.1-fold (95% confidence interval 1.346.91, P=0.008). The predictive capacity of s-VEGF levels on PFS was most pronounced in the DLBCLs of non-germinal center subtype. In contrast to serum data, VEGF mRNA expression in the lymphoma tissue did not predict outcome, and no correlation was found between s-VEGF levels and lymphoma VEGF expression. Conclusion Pretreatment s-VEGF level is a predictor of PFS after chemoimmunotherapy and may help to further stratify high-risk DLBCL patients into low- and high-risk groups.}}, author = {{Riihijarvi, Sari and Nurmi, Heidi and Holte, Harald and Bjorkholm, Magnus and Fluge, Oystein and Pedersen, Lars Moller and Fjordén, Karin and Jerkeman, Mats and Eriksson, Mikael and Leppa, Sirpa}}, issn = {{1600-0609}}, keywords = {{diffuse large B-cell lymphoma; prognostic factors; vascular endothelial; growth factor; serum; ELISA; gene expression; exon array}}, language = {{eng}}, number = {{5}}, pages = {{395--402}}, publisher = {{Wiley-Blackwell}}, series = {{European Journal of Haematology}}, title = {{High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy}}, url = {{http://dx.doi.org/10.1111/ejh.12005}}, doi = {{10.1111/ejh.12005}}, volume = {{89}}, year = {{2012}}, }